Journal of the American Academy of Dermatology

The most recent articles from: J. Am. Acad. Dermatol. July 2019

J. Am. Acad. Dermatol. · Jul 2019

Randomized Controlled Trial Multicenter Study

A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.

Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease. ⋯ Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis.

read on… or not…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,662 articles already indexed!